Skip to main content

Sara Cunningham Hall, Mike Catelani, Linda Couto, Paul Pockros, Robert Lanford, Jonathan Coates, Ken Reed, Arthur Riggs, Stephen Edwards

Tacere Therapeutics, a newly founded RNAi-based drug developer, said this week that it has appointed former Benitec CEO Sara Cunningham Hall as its president and CEO.
Before working at Benitec, Cunningham Hall was founder and vice president of intellectual property and business development at Avocel, which was acquired by Benitec in 2004.
Tacere also said that former Benitec CFO Mike Catelani has been named senior vice president and CFO, and former Benitec Preclinical Director Linda Couto has been named vice president of research and development.
The company also announced its scientific advisory board, which includes Paul Pockros of the Scripps Clinic Research Consortium, Robert Lanford of the Southwest Foundation for Biomedical Research, and Jonathan Coates, CEO of Avexa. (See related story, this issue, for further details on Tacere.

Ken Reed, co-founder of Benitec, has accepted a two-year sabbatical at the City of Hope in Duarte, Calif.
According to Reed, he will be working as a visiting investigator with Arthur Riggs, director of the City of Hope’s Beckman Research Institute.
Before founding Benitec, Reed was director of the Queensland Agriculture Biotechnology Center. He holds a PhD and MS in biochemistry from Australian National University and a BS in biochemistry/chemistry from Melbourne University.

The US Environmental Protection Agency announced that it has hired Stephen Edwards as systems biologist within the National Health and Environmental Effects Research Laboratory in Research Triangle Park, NC.
Edwards most recently served as a senior research scientist and research fellow at Merck’s Rosetta Inpharmatics subsidiary.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.